FDA: Gene therapy maker submitted manipulated data before drug was approved

The FDA said Tuesday the maker of a newly approved $2 million gene therapy was aware that some of the testing data in its application to the agency was manipulated. But it said the treatment, called Zolgensma, should remain on the market.

View original article
Contributor: Laurie McGinley